Personalized approach to ovarian stimulation achieves high ART pregnancy rates

Lyon, France -- An international group of fertility specialists has developed an easy-to use mathematical formula that allows a personalised approach to ovarian stimulation therapy for women seeking fertility treatment. Clinical tests demonstrated that when clinicians used the formula (or algorithm) to calculate the best starting dose for each patient, both the number of oocytes retrieved and pregnancy rates rose.

Professor Franois Olivennes told the 23rd annual meeting of the European Society of Human Reproduction and Embryology today (Monday 2 July) that the algorithm was based on four factors that predicted ovarian response and that were measured routinely when women were evaluated for fertility treatment: normal (or basal) levels of follicle stimulating hormone (FSH), body mass index, age and the number of small growing (antral) follicles in the ovary detected during screening.

This FSH dose algorithm is simple and easy to use and utilises readily available patient characteristics, said Prof Olivennes, coordinator of the Centre de FIV Eylau La Muette, Paris, France. It is the first to be tested in a prospective multi-national clinical study and it provided each patient with an individualised starting dose of FSH, which could be maintained throughout treatment and resulted in an excellent treatment outcome as testified by the number of oocytes retrieved and the high pregnancy rates.

This approach should enable us to improve patient management, treatment outcomes and safety by reducing the chances of having to either cancel cycles because the ovaries have not been stimulated enough or of ovarian hyperstimulation syndrome (OHSS) developing because the ovaries have been over-stimulated.

Moderate or severe OHSS can occur in 3-8% of IVF cycles [1]. Moderate OHSS can be accompanied by nausea and vomiting. Severe OHSS, which is an uncommon event, can be accompanied by ovarian enlargement and fluid imbalances, sometimes resulti

Contact: Emma Mason
European Society for Human Reproduction and Embryology

Page: 1 2 3

Related biology news :

1. Personalized medicine, future of pharmaceuticals explored in UH lecture
2. Personalized treatments according to type of obesity
3. Researchers use new approach to predict protein function
4. New approach to pulmonary hypertension shows promise
5. New approaches to endometriosis treatment -- mouse experiments point the way
6. Reconstructing the biology of extinct species: A new approach
7. Screening approach leads to discovery of gene linked to breast cancer
8. In new statistical approach, data decide model
9. Bigelow Laboratory Scientists develop new approach to study marine microbes
10. New understanding of schizophrenia could lead to new treatment approaches
11. Cheaper, better disease treatments expected from faster approach to developing antibodies

Post Your Comments:

(Date:9/30/2015)... Fla. , Sept. 30, 2015  The U.S. ... month issued another key ruling in favor of ... that Korean fingerprint scanner company Suprema and its U.S. ... of 1930, a trade provision that declares it unlawful ... trade, by infringing two of Crossmatch,s patents, the 5,900,993 ...
(Date:9/28/2015)...  The monitoring of vital signs, such as ... an essential component of patient assessment. Changes in ... a patient,s condition. However, in general care areas ... during routine observation rounds only once every four ... these observation rounds, the warning signs can go ...
(Date:9/24/2015)... NEW YORK , Sept. 24, 2015  EyeLock ... will be showcasing its award winning and latest technology ... Anaheim, California . EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA.   EyeLock,s platform uses video technology to deliver a ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... ... October 13, 2015 , ... SonaCare ... announced today that it received de novo clearance from the U.S. Food and ... the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound ...
(Date:10/12/2015)... Calif. and BRUSSELS , Oct. ... (Euronext Brussels: UCB) today presented additional findings from an exploratory ... The findings were presented today in an oral plenary ... (ASBMR) 2015 Annual Meeting in Seattle . ... --> The small exploratory sub-study data showed ...
(Date:10/12/2015)... 12, 2015  Rebiotix Inc. today announced that ... its lead Microbiota Restoration Therapy (MRT) RBX2660 as ... Clostridium difficile (C diff) infection, a ... 29,000 deaths in the U.S. annually. 1 ... was founded to revolutionize the treatment of debilitating ...
(Date:10/12/2015)... SAN DIEGO , Oct. 12, 2015 /PRNewswire/ ... for debilitating allergic and inflammatory diseases and conditions, ... Series A preferred stock financing. Concurrent with the ... also entered into a Loan and Security Agreement ... borrow up to $7 million. Patara will use ...
Breaking Biology Technology:
Cached News: